Invokana, Jardiance Side Effects Caused Diabetic Ketoacidosis: Lawsuit

A recently filed product liability lawsuit indicates that side effects of Invokana and Jardiance, which are both member of a new class of diabetes drugs, caused a Utah woman to suffer severe health complications due to diabetic ketoacidosis. 

The complaint (PDF) was brought last week by Patricia MacMurray in the U.S. District Court for the Southern District of Indiana, naming Johnson & Johnson’s Janssen Pharmaceuticals subsidiary, as well as Eli Lilly and Boehringer Ingelheim Pharmaceuticals, Inc., as defendants.

MacMurray indicates that she began taking Invokana in early 2015, and then began taking Jardiance in March 2015. Shortly thereafter, MacMurray developed diabetic ketoacidosis, which involves a dangerous buildup of acid levels in the blood, which caused her to be hospitalized for seven, with treatment in the intensive care unit (ICU).

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Invokana and Jardiance are both part of a new-generation of type-2 diabetes treatments introduced in recent years, known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. Although the medications have only been on the market for a few years, the drug makers have aggressively promoted the treatments as superior alternatives to older diabetes medications. Other members of the same class include Farxiga, Invokamet, Glyxambi and Xigduo XR.

Concerns about the potential link between Invokana, Jardiance and ketoacidosis emerged in May 2015, when the FDA indicated that during the first 15 months the new class of diabetes drugs was on the market, more than 20 adverse event reports were received involving individuals using an SGLT2 inhibitor who required emergency room treatment or hospitalization due to diabetic ketoacidosis, ketosis, acidosis or other related conditions.

Ketoacidosis can result in symptoms like difficulty breathing, nausea, vomiting, abdominal pain, confusion, fatigue or sleepiness, often requiring urgent medical treatment and potentially resulting in severe health consequences.

Although diabetic ketoacidosis is commonly associated with type 1 diabetes, it is not normally seen among individuals diagnosed with type 2 diabetes, which is the type of diabetes Jardiance and Invokana are approved to treat. Type 2 diabetes is an acquired and curable condition, while type 1 diabetes is usually something someone is born with and persists for life.

In addition to concerns about ketacidosis, a number of lawsuits over Invokana kidney problems have been filed against Janssen, alleging the drug maker also failed to adequately warn that the medication may increase the risk of kidney failure and other complications.

In May 2015, the Institute for Safe Medication Practices (ISMP) conducted a detailed review of adverse event reports submitted to the FDA during the first year Invokana was on the market, and identified a potential risk of kidney damage with Invokana and other SGLT2 inhibitors, raising questions about whether the benefits provided by the medication justify the risk.

In June 2016, the FDA released a new Invokana safety warning, indicating that the medication may increase the risk of acute kidney injury and other severe health problems.

A number of lawyers are now reviewing potential Jardiance lawsuits and Invokana lawsuits for individuals hospitalized due to ketoacidosis and kidney damage. Plaintiffs claim that the drug makers placed their desire for profits before consumer safety, but withholding information about the risks associated with the new generation diabetes treatments.

Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted today)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 2 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.